International Journal of Hematology

DOI: 10.1007/s12185-017-2255-8 Pages: 562-572

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma

1. Nagoya City University Hospital, Department of Hematology and Oncology

2. Kameda Medical Center, Department of Hematology and Oncology

3. National Hospital Organization Okayama Medical Center, Department of Hematology

4. Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Department of Hematology

5. Sanofi K.K.

6. Japanese Red Cross Medical Center, Department of Hematology

Correspondence to:
Masaki Ri
Tel: +8152-851-5511
Email: rrmasaki@ybb.ne.jp

Close

Abstract

To evaluate the efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells (HSCs) for autologous transplantation in Japanese patients with multiple myeloma (MM). In a randomized study, patients received G-CSF (filgrastim, 400 µg/m2/day) for 4 days prior to the first dose of plerixafor. Starting on Day 4 evening and for up to 4 days, patients received either plerixafor (240 µg/kg/day) + G-CSF group (PG group) or G-CSF alone (G group). Daily apheresis started on Day 5 for up to 4 days, or until ≥6 × 106 CD34+ cells/kg were collected. A total of 7 patients were randomized in each treatment group. Five patients in PG group and no patients in G group achieved a collection of ≥6 × 106 CD34+ cells/kg in ≤2 days of apheresis [difference of 71.4% (90%CI 29–100%)]. These results were supported by the shorter median time to collect ≥6 × 106 CD34+ cells/kg (2 days in PG group; no patient in G group). The incidence of treatment emergent adverse events (TEAEs) was higher in PG group than in G group. Plerixafor was well tolerated, and effective for the mobilization/collection of peripheral HSCs for autologous transplantation in Japanese patients with MM.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge